Willow Biosciences Inc.

WLLW

CA97111B4047

Pharmaceuticals

End-of-day quote Toronto S.E. Other stock markets 18:00:00 2024-07-01 EDT			5-day change	1st Jan Change
0.115 ^CAD	+4.55%		+4.55%	+15.00%

06-26	Willow Biosciences Provides Corporate Update and Signs New Partnered Program	MT
06-26	Willow Biosciences Brief: Announced multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients	MT

Willow Biosciences Inc :. Opens the Market

January 15, 2020 at 02:36 pm

TORONTO, Jan. 15, 2020 /CNW/ - Trevor Peters, President, Chief Executive Officer and Director, Willow Biosciences Inc. (WLLW), joined Dani Lipkin, Innovation Sector Head, Capital Formation, Toronto Stock Exchange and TSX Venture Exchange, to open the market. Willow is a Canadian biotechnology company based in Calgary, Alberta, that produces high purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow Biosciences Inc. commenced trading on Toronto Stock Exchange on December 5, 2019.

Willow Biosciences Inc. Opens the Market (CNW Group/TMX Group Limited)

SOURCE TMX Group Limited

Latest news about Willow Biosciences Inc.

Willow Biosciences Provides Corporate Update and Signs New Partnered Program	06-26	MT
Willow Biosciences Brief: Announced multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients	06-26	MT
Willow Biosciences Brief: Expanding into the high growth biopesticide sector with addition of new partnered program	06-26	MT
Willow Biosciences Brief: Announces its first patent being issued; Anticipates filing another five patents in 2024 primarily related to its steroid production platform	06-26	MT
Willow Biosciences Brief: Anticipates revenue of over $1.0 million in Q2, and over $3.5 million for 2024 on existing programs	06-26	MT
Willow Biosciences Brief: Providing Corporate Update and Signs New Partnered Program	06-26	MT
Willow Biosciences to Raise Up to $3 Million Via Brokered Private Placement; Shares Jumped 24% on Friday	06-03	MT
Willow Biosciences Brief: Announcing Brokered Private Placement Offering To Raise Up To $3 Million	06-03	MT
Willow Biosciences Inc. announced that it expects to receive CAD 3 million in funding	06-02	CI
Willow Biosciences Signs Multi-Product Development, Licensing Partnership With Laurus Lab	05-30	MT
Willow Biosciences Brief: Announcing Multi-product Development and Licensing Partnership With Laurus Lab	05-30	MT
Willow Biosciences Inc. Announces Multi-Product Development and Licensing Partnership with Laurus Labs	05-30	CI
Willow Biosciences Brief: Reiterating its Expectations of at least doubling its full year 2024 revenues, As Reports Q1 Results	05-13	MT
Willow Biosciences Inc. Provides Earnings Guidance for the Fiscal Year 2024	05-13	CI
Willow Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Willow Biosciences Narrows 2023 Loss YOY	04-01	MT
Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Willow Biosciences Announces Second Strategic Investment From Kalsec	03-01	MT
Willow Biosciences Secures Strategic Investment From Kalsec to Develop Natural Food Ingredient	02-21	MT
Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc.	02-19	CI
Willow Biosciences Enters Partnership With Global Ingredient Manufacturer	01-31	MT
Willow Biosciences Inc. Announces Collaboration with Global Active Pharmaceutical Ingredient Manufacturer to Develop A More Sustainable, Cost-Effective Manufacturing Process for A Large Volume Global Market	01-31	CI
Willow Biosciences Announces Collaboration with Active Pharmaceutical Ingredient Manufacturer to Manufacture More Sustainable, Cost-Effective Manufacturing Route for Their Largest Product Sold Globally	01-31	CI
Willow Biosciences Announces Collaboration With Enterin	01-16	MT
Willow Biosciences Inc. Announces Collaboration with Enterin, Inc. to Develop Sustainable Interimates and Active Pharmaceutical Ingredients	01-16	CI

Chart Willow Biosciences Inc.

Duration

Period

More charts

Company Profile

Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.

Sector

Pharmaceuticals

Calendar

2024-07-26 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
WILLOW BIOSCIENCES INC.	+15.00%	10.19M
SAMSUNG BIOLOGICS CO.,LTD.	+6.58%	39.05B
BIOGEN INC.	-11.57%	33.74B
UCB	+79.15%	28.54B
BIOMARIN PHARMACEUTICAL INC.	-14.73%	15.59B
INCYTE CORPORATION	-6.00%	13.69B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.55%	11.44B
ALTEOGEN INC.	+166.50%	10.66B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.80%	9.27B
SWEDISH ORPHAN BIOVITRUM AB	+4.19%	9.13B